Selecta Biosciences' Dr. Carsten Brunn on Gene Therapy with AAV Vectors

Cell & Gene: The Podcast

English - February 03, 2022 09:00 - 20 minutes - 14.5 MB - ★★★★★ - 35 ratings
Life Sciences Science Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Cellevolve Bio's Dr. Derrell Porter on the Need for Diversity and Inclusion in Biotech

Next Episode: REGENXBIO's Nina Hunter, Ph.D. Details the Accelerated Approval Pathway for Gene Therapies

We love to hear from our listeners. Send us a message.

Selecta Biosciences' President and CEO Dr. Carsten Brunn details the company's ImmTOR platform, which can mitigate unwanted immune responses that cause immune-related toxicities that impose significant treatment challenges with current therapies.